Also known as: FPF-1070 · FPE 1070 · Cerebroprotein hydrolysate · Porcine brain peptide preparation
Updated 23 sources
Every Cerebrolysin protocol on file, 11 in all, labelled by where each number came from. 1 have titration steps, each step is worked out in U-100 units for a 60 mg vial + 3 mL water.
Who: Adults and older adults with Alzheimer-type or vascular dementia.
Note: Label dose: 10 to 30 mL a day, which is 2152 to 6456 mg of peptide preparation at 215.2 mg/mL. From the second course the label allows 2 to 3 doses a week instead of daily. The maker's card says 2 to 4 courses a year. Up to 10 mL may be injected IV; more goes in an infusion.
Who: Adults after ischemic stroke.
Note: Label dose: 20 to 50 mL a day, which is 4304 to 10760 mg of peptide preparation at 215.2 mg/mL. Given as a diluted infusion over about 15 to 60 minutes.
Who: Adults after hemorrhagic stroke.
Note: Label dose: 30 to 50 mL a day, which is 6456 to 10760 mg of peptide preparation at 215.2 mg/mL. Given as a diluted infusion.
Who: Adults with concussion or brain contusion.
Note: Label dose: 20 to 50 mL a day, which is 4304 to 10760 mg of peptide preparation at 215.2 mg/mL. Given as a diluted infusion.
Who: 1,070 patients with acute ischemic stroke in Asia, treated within 12 hours, plus aspirin.
Note: Trial dose: 30 mL a day, which is 6456 mg of peptide preparation at 215.2 mg/mL. The primary endpoint was neutral; a post hoc trend favored Cerebrolysin in severe strokes.
Who: Stroke patients starting 24 to 72 hours after onset, alongside a 21 day rehab program.
Note: Trial dose: 30 mL a day, which is 6456 mg of peptide preparation at 215.2 mg/mL. The abstract does not state the route; the label sends volumes above 10 mL to infusion. Arm function was better at day 90; the authors call the trial exploratory.
Who: 185 patients with moderate to severe TBI (Glasgow Coma Score 6 to 12), on top of usual care.
Note: Trial dose: 50 mL a day (10760 mg) for 10 days, then 10 mL a day (2152 mg) in two more 10 day cycles, at 215.2 mg/mL. The abstract does not give the gap between cycles or the route. Small-to-medium benefit at days 30 and 90, with safety similar to placebo.
Who: Patients with moderate to moderately severe Alzheimer's disease, in arms of 10, 30 or 60 mL.
Note: Trial arms: 10, 30 or 60 mL per dose, which is 2152, 6456 or 12912 mg of peptide preparation at 215.2 mg/mL. Each dose was diluted to a 100 mL infusion. All three doses improved global function at week 24.
Who: Healthy adults using it as a nootropic; not studied in this group.
Note: Community dose: 5 mL a day, which is 1076 mg of peptide preparation at 215.2 mg/mL. 5 mL is the label's maximum for one IM injection. Some users go to 10 mL split between two sites. One MS forum member reports 5 mL IM about 5 times a week, in cycles with breaks.
Who: Healthy adults using it as a nootropic.
Note: Community dose: 10 mL a day, which is 2152 mg of peptide preparation at 215.2 mg/mL. The label caps a single IM injection at 5 mL, which is why users split it. The source gives no course length for this dose.
Who: Research powder sold by mg, not the pharmaceutical solution.
| When | Dose | U-100 units (60 mg vial + 3 mL water) |
|---|---|---|
| Week 1 | 20 mg | 100 units · 1 mL |
| Week 2 | 24 mg | 120 units · 1.2 mL(2 draws) |
| Week 3 | 28 mg | 140 units · 1.4 mL(2 draws) |
| Weeks 4 to 12 | 32 mg | 160 units · 1.6 mL(2 draws) |
Note: Amounts are mg of a 60 mg research powder mixed with 3 mL of water (20 mg/mL), not mL of the drug. One guide calls this ramp community-derived. These amounts are roughly 100 to 300 times below clinical courses and come from no trial. The pharmaceutical is not meant for insulin-syringe subQ dosing.
Doses shown are what sources report, labelled by origin. Not medical advice.
| Water | Strength | 20 mgdose, units | 32 mgdose, units |
|---|---|---|---|
| 60 mg vial | |||
| 3 mLCompetitor guide | 20 mg/mL | 1001 mL | 1601.6 mL2 draws |
Doses shown are what sources report, labelled by origin. Not medical advice.
Calculate with this peptideYour vial, your water, your dose: Cerebrolysin in syringe units, with the math shown.Diluent: Bacteriostatic water (research powder only)
Water volumes sources use: 3 mL
Only the research powder is reconstituted. The pharmaceutical is ready to use; above 10 mL it is diluted in 0.9% saline, Ringer's or 5% glucose (to at least 100 mL total per the maker's card), all tested compatible over 24 hours. Never mix it with balanced amino acid solutions, lipid solutions or anything that shifts pH.
Do not double the next dose. Courses are planned as a set, so a missed day is a question for the treating clinician.
By the Austrian label: 10 to 30 mL a day for dementia (4 week courses, 5 days a week), 20 to 50 mL a day for ischemic stroke (10 to 21 days), 30 to 50 mL for hemorrhagic stroke (10 to 21 days) and 20 to 50 mL for brain injury (7 to 30 days).
The drug is dosed in mL at 215.2 mg per mL, so 5 mL is 1,076 mg, 10 mL is 2,152 mg, 30 mL is 6,456 mg and 50 mL is 10,760 mg. Research powders sold by mg (20 to 32 mg a day in one guide) are a different product and far smaller.
No. The pharmaceutical is a ready-to-use solution. Only research powders sold by mg are mixed, typically 60 mg with 3 mL of bacteriostatic water.
12 sources, each checked by date. Record updated Oct 24, 2026. Numbers are restated in our own words and labelled by where they came from.
Back to the full Cerebrolysin page for side effects, storage, stacks and legal status.